Whittier Trust’s GenMark Diagnostics, Inc GNMK Stock Holding History

Whittier Trust’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-196	Closed	-$1K	–	1354
2017 Q4	$1K	Buy	+196	New	+$1.18K	﹤0.01%	1265

Other funds holding GNMK

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Whittier Trust's GNMK Position: Q1 2018 in Review

Whittier Trust sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2018, closing a stake of 196 shares — an estimated $1K sold.

Whittier Trust first reported a position in GNMK in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 98 funds tracked by Wall St. Rank hold GNMK as of Q1 2018.

Whittier Trust reported no remaining GenMark Diagnostics, Inc position as of Q1 2018 after selling out during the quarter.
Whittier Trust sold 196 GenMark Diagnostics, Inc shares in Q1 2018, an estimated $1K.
Whittier Trust first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 1 quarter.
Whittier Trust's GenMark Diagnostics, Inc position peaked at $1K in Q4 2017.
98 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2018.

Based on Whittier Trust's 13F filing for Q1 2018, filed 1 May 2018.